L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.82 NOK -1.16% Market Closed
Market Cap: 338.3m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Intrinsic Value

LYTIX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one LYTIX stock under the Base Case scenario is 1.02 NOK. Compared to the current market price of 6.82 NOK, Lytix Biopharma AS is Overvalued by 85%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LYTIX Intrinsic Value
1.02 NOK
Overvaluation 85%
Intrinsic Value
Price
L
Worst Case
Base Case
Best Case

Valuation Backtest
Lytix Biopharma AS

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for LYTIX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about LYTIX?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Lytix Biopharma AS

Provide an overview of the primary business activities
of Lytix Biopharma AS.

What unique competitive advantages
does Lytix Biopharma AS hold over its rivals?

What risks and challenges
does Lytix Biopharma AS face in the near future?

Summarize the latest earnings call
of Lytix Biopharma AS.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Lytix Biopharma AS.

Provide P/S
for Lytix Biopharma AS.

Provide P/E
for Lytix Biopharma AS.

Provide P/OCF
for Lytix Biopharma AS.

Provide P/FCFE
for Lytix Biopharma AS.

Provide P/B
for Lytix Biopharma AS.

Provide EV/S
for Lytix Biopharma AS.

Provide EV/GP
for Lytix Biopharma AS.

Provide EV/EBITDA
for Lytix Biopharma AS.

Provide EV/EBIT
for Lytix Biopharma AS.

Provide EV/OCF
for Lytix Biopharma AS.

Provide EV/FCFF
for Lytix Biopharma AS.

Provide EV/IC
for Lytix Biopharma AS.

Show me price targets
for Lytix Biopharma AS made by professional analysts.

What are the Revenue projections
for Lytix Biopharma AS?

How accurate were the past Revenue estimates
for Lytix Biopharma AS?

What are the Net Income projections
for Lytix Biopharma AS?

How accurate were the past Net Income estimates
for Lytix Biopharma AS?

What are the EPS projections
for Lytix Biopharma AS?

How accurate were the past EPS estimates
for Lytix Biopharma AS?

What are the EBIT projections
for Lytix Biopharma AS?

How accurate were the past EBIT estimates
for Lytix Biopharma AS?

Compare the revenue forecasts
for Lytix Biopharma AS with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Lytix Biopharma AS and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Lytix Biopharma AS against its competitors.

Analyze the profit margins
(gross, operating, and net) of Lytix Biopharma AS compared to its peers.

Compare the P/E ratios
of Lytix Biopharma AS against its peers.

Discuss the investment returns and shareholder value creation
comparing Lytix Biopharma AS with its peers.

Analyze the financial leverage
of Lytix Biopharma AS compared to its main competitors.

Show all profitability ratios
for Lytix Biopharma AS.

Provide ROE
for Lytix Biopharma AS.

Provide ROA
for Lytix Biopharma AS.

Provide ROIC
for Lytix Biopharma AS.

Provide ROCE
for Lytix Biopharma AS.

Provide Gross Margin
for Lytix Biopharma AS.

Provide Operating Margin
for Lytix Biopharma AS.

Provide Net Margin
for Lytix Biopharma AS.

Provide FCF Margin
for Lytix Biopharma AS.

Show all solvency ratios
for Lytix Biopharma AS.

Provide D/E Ratio
for Lytix Biopharma AS.

Provide D/A Ratio
for Lytix Biopharma AS.

Provide Interest Coverage Ratio
for Lytix Biopharma AS.

Provide Altman Z-Score Ratio
for Lytix Biopharma AS.

Provide Quick Ratio
for Lytix Biopharma AS.

Provide Current Ratio
for Lytix Biopharma AS.

Provide Cash Ratio
for Lytix Biopharma AS.

What is the historical Revenue growth
over the last 5 years for Lytix Biopharma AS?

What is the historical Net Income growth
over the last 5 years for Lytix Biopharma AS?

What is the current Free Cash Flow
of Lytix Biopharma AS?

Discuss the annual earnings per share (EPS)
trend over the past five years for Lytix Biopharma AS.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Lytix Biopharma AS

Current Assets 63.3m
Cash & Short-Term Investments 50.5m
Receivables 12.8m
Other Current Assets 1k
Non-Current Assets 548k
PP&E 548k
Current Liabilities 12.5m
Accounts Payable 3.6m
Other Current Liabilities 8.9m
Non-Current Liabilities 41k
Long-Term Debt 41k
Efficiency

Earnings Waterfall
Lytix Biopharma AS

Revenue
4m NOK
Operating Expenses
-100.8m NOK
Operating Income
-96.8m NOK
Other Expenses
8.9m NOK
Net Income
-87.9m NOK

Free Cash Flow Analysis
Lytix Biopharma AS

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q2, Lytix Biopharma highlighted promising results from their LTX-315 Phase II studies, including an 86% average tumor size reduction in basal cell carcinoma patients. A new neoadjuvant study, NeoLIPA, is set to begin, evaluating LTX-315 with pembrolizumab in early-stage melanoma, aiming for a 40% response rate. The company raised NOK 50 million, extending their cash runway into 2025, and reported cash of NOK 60 million at quarter-end. Overall, Lytix is well-positioned to pursue commercialization opportunities as it continues to produce encouraging clinical data.

What is Earnings Call?
Fundamental Scores

LYTIX Profitability Score
Profitability Due Diligence

Lytix Biopharma AS's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Negative 1-Year Revenue Growth
Negative Operating Income
Negative Net Income
Negative ROE
17/100
Profitability
Score

Lytix Biopharma AS's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

LYTIX Solvency Score
Solvency Due Diligence

Lytix Biopharma AS's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Lytix Biopharma AS's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LYTIX Price Targets Summary
Lytix Biopharma AS

Wall Street analysts forecast LYTIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LYTIX is 16.32 NOK with a low forecast of 16.16 NOK and a high forecast of 16.8 NOK.

Lowest
Price Target
16.16 NOK
137% Upside
Average
Price Target
16.32 NOK
139% Upside
Highest
Price Target
16.8 NOK
146% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for LYTIX?

Click here to dive deeper.

Dividends

Lytix Biopharma AS
does not pay dividends
Shareholder Yield

Current shareholder yield for LYTIX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Lytix Biopharma AS

Country

Norway

Industry

Biotechnology

Market Cap

338.3m NOK

Dividend Yield

0%

Description

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

Contact

OSLO
Oslo
Hoffsveien 4
www.lytixbiopharma.com

IPO

2021-06-14

Employees

-

Officers

Co-Founder & CEO
Dr. Oystein Rekdal Ph.D.
Chief Financial Officer
Mr. Gjest Breistein M.Sc.
Chief Technology Officer
Dr. Gry Stensrud Ph.D.
Chief Scientific Officer
Dr. Baldur Sveinbjørnsson Ph.D.
Head of IR & Communication Manager
Mr. Ole Peter Nordby
Head of Clinical Operations
Jacqueline Earabino

See Also

Discover More
What is the Intrinsic Value of one LYTIX stock?

The intrinsic value of one LYTIX stock under the Base Case scenario is 1.02 NOK.

Is LYTIX stock undervalued or overvalued?

Compared to the current market price of 6.82 NOK, Lytix Biopharma AS is Overvalued by 85%.

Back to Top